Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein Sells 1,579 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 1,579 shares of the firm’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $71.50, for a total value of $112,898.50. Following the completion of the sale, the chief financial officer now owns 113,288 shares in the company, valued at approximately $8,100,092. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sara Bonstein also recently made the following trade(s):

• On Wednesday, May 14th, Sara Bonstein sold 1,634 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total value of $107,206.74.
• On Tuesday, May 13th, Sara Bonstein sold 8,870 shares of Insmed stock. The shares were sold at an average price of $67.81, for a total value of $601,474.70.

Insmed Stock Up 0.8%

Shares of Insmed stock opened at $73.69 on Thursday. Insmed Incorporated has a 12-month low of $55.74 and a 12-month high of $84.91. The firm has a market capitalization of $13.42 billion, a PE ratio of -13.18 and a beta of 0.84. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The stock’s fifty day moving average is $69.32 and its 200-day moving average is $72.99.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The company had revenue of $92.82 million during the quarter, compared to analysts’ expectations of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.06) EPS. Equities analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on INSM. Stifel Nicolaus reduced their price objective on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a report on Friday, February 21st. Truist Financial raised their price objective on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Bank of America boosted their target price on Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a report on Thursday, March 20th. Wells Fargo & Company increased their price target on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $100.00 price target on shares of Insmed in a research report on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $96.73.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in INSM. Blue Trust Inc. lifted its position in shares of Insmed by 25.7% in the 4th quarter. Blue Trust Inc. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 503 shares in the last quarter. Spire Wealth Management purchased a new position in Insmed during the 4th quarter worth approximately $47,000. Jennison Associates LLC raised its stake in Insmed by 0.6% during the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock valued at $53,424,000 after purchasing an additional 4,560 shares during the period. abrdn plc lifted its holdings in shares of Insmed by 159.5% in the fourth quarter. abrdn plc now owns 289,653 shares of the biopharmaceutical company’s stock valued at $19,998,000 after purchasing an additional 178,041 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Insmed by 3.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company’s stock valued at $446,000 after purchasing an additional 186 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.